Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.

about

Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.

P2860

Q33827405-7B5A41F7-13D4-4980-820C-6C55445A6A60 Q41646527-462C1CFC-D4FB-424F-A965-74E2620E6B96

P2860

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.

Item

http://www.wikidata.org/entity/Q38056750

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.

@en

type

Item

label

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.

@en

prefLabel

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.

@en

P1476

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.

@en

P2093

Isabelle Wauters

http://www.w3.org/2001/XMLSchema#string

Johan Vansteenkiste

http://www.w3.org/2001/XMLSchema#string

P2860

September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents

Cloning and expression of the human erythropoietin gene

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

P304

1383-1390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.12.117

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23113603

http://www.w3.org/2001/XMLSchema#string

P921

Darbepoetin alfa

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.

about

P2860

P2860

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921